Fig. 3.

Antitumor activities of FMS. (A) Antibody-mediated cytotoxicity (CDC) of antisera from FMS-treated mice to LLC1 and TC-1 tumor cells was determined by a lactose dehydrogenase kit. The value of antisera heated at 56 °C for 30 min (HI-antisera) is indicative of the complement depletion effect. (B) Comparison of antitumor effects between preventive (Exp-1) and therapeutic (Exp-2) FMS treatment in vivo. Control is PBS-treated mice with tumor inoculation. (C) FMS treatment suppressed tumor-associated cytokines and chemokines production in vivo. Serum samples were collected at indicated time after tumor inoculation and examined by Beadlyte mouse 21-pex kits. (D and E) Distinct binding intensities of plant lectins (AAL, 2 μg/mL; UEA-I, 10 μg/mL) and anti-Globo H mAb (MBr1, 0.5mg/mL) to Globo H (GH), FMS and F3 were determined by using the fabricated glycan microarray. (F–H) DFMS (low-Fuc content of FMS) treatment reduced CDC (F) and antitumor activities in vivo, as assessed by tumor growth curves (G) and MCP-1 production levels (H). Values show the means ± SD (n ≈ 3–5 for each experiment). n.d., not detectable; NS, no statistical significant.